Comprehensive profiling and kinetic studies of glycated lysine residues in human serum albumin
- PMID: 35538229
- DOI: 10.1007/s00216-022-04108-1
Comprehensive profiling and kinetic studies of glycated lysine residues in human serum albumin
Abstract
Lysine residues of proteins slowly react with glucose forming Amadori products. In hyperglycemic conditions, such as diabetes mellitus, this non-enzymatic glycation becomes more pervasive causing severe medical complications. The structure and conformation of a protein predisposes lysine sites to differing reactivity influenced by their steric availability and amino acid microenvironment. The goal of our study was to identify these sites in albumin and measure glycation affinities of lysine residues. We applied a bottom-up approach utilizing a combination of three LC-MS instruments: timsTOF, Orbitrap, and QTRAP. To prove applicability to samples of varying glycemic status, we compared in vitro glycated and non-glycated HSA, as well as diabetic and non-diabetic individual samples. The analysis of lysine glycation affinities based on peptide intensities provide a semi-quantitative approach, as the results depend on the mass spectrometry platform used. We found that glycation levels based on multiple reaction monitoring (MRM) quantitation better reflect individual glycemic status and that the glycation percentage for each site is in linear relation to all other sites. To develop an approach which more accurately reflects glycation affinity, we developed a kinetics model which uses results from stable isotope dilution HPLC-MRM methodology. Through glycation of albumin at different glucose concentrations, we determine the rate constants of glycation for every lysine residue by simultaneous comparative analysis.
Keywords: Diabetes mellitus; Glycated albumin; Glycated proteins; Isotope labeling; Kinetics of glycation; Mass spectrometry.
© 2022. Springer-Verlag GmbH Germany, part of Springer Nature.
References
-
- Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. https://doi.org/10.1016/j.diabres.2019.107843 .
-
- DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. The Lancet. 2018;391:2449–62. https://doi.org/10.1016/S0140-6736(18)31320-5 . - DOI
-
- Fowler MJ. Microvascular and macrovascular complications of diabetes. Clinical Diabetes. 2008;26:77–82. https://doi.org/10.2337/diaclin.26.2.77 . - DOI
-
- Semba RD, Nicklett EJ, Ferrucci L. Does accumulation of advanced glycation end products contribute to the aging phenotype? J Gerontol A Biol Sci Med Sci. 2010;65A:963–75. https://doi.org/10.1093/gerona/glq074 . - DOI - PMC
-
- Ceriello A, Catrinoiu D, Chandramouli C, Cosentino F, Dombrowsky AC, Itzhak B, et al. Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. Cardiovasc Diabetol. 2021;20:218. https://doi.org/10.1186/s12933-021-01408-1 . - DOI - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
